Elevated DLST expression among high-risk neuroblastoma patients correlated with an enrichment of genes within the OXPHOS network, while OXPHOS inhibition perturbed the aggressive properties of MYCN-amplified neuroblastoma xenografts [50]. The gene discussed is MYCN; the disease is neuroblastoma.